Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

EicOsis LLC
Profile last edited on: 1/17/2018      CAGE: 6TV05      UEI: EM8CCFVCTV69

Business Identifier: Safe and effective, non-narcotic therapies for moderate to severe pain and inflammation
Year Founded
2011
First Award
2014
Latest Award
2022
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

1407 Nutmeg Lane
Davis, CA 95618
   (650) 455-0388
   info@eicosis.com
   www.eicosis.com
Location: Single
Congr. District: 03
County: Yolo

Public Profile

EicOsis is developing a first-in-class therapy of a once daily, oral treatment for neuropathic and inflammatory pain in humans and animals: non-opioid therapeutics. Pain is an enormous emotional and economic burden. Current therapies have dose limiting side effects in addition to being ineffective in more than 3 of 4 patients. EicOsis discovered a novel enzyme target to alleviate pain without the dose limiting or narcotic side effects that exist in current treatments.

Extent of SBIR involvement

User Avatar
Phase I Awards
3
Phase II Awards
1
Conversion Rate
33.33%
Phase I Dollars
$771,775
Phase II Dollars
$1,515,862
Total Awarded
$2,287,637

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2022 1 NIH $279,136
Project Title: Identification of mechanism-based therapies to treat arrhythmogenic cardiomyopathy by resolving perturbations in regulatory lipid signaling
2019 1 NIH $268,196
Project Title: Inhibiting Soluble Epoxide Hydrolase as a Treatment for Chemotherapy Inducedperipheral Neuropathic Pain
2017 2 NIH $1,740,305
Project Title: sEH Inhibitors to Treat Neuropathic Pain

Key People / Management

  Bruce Hammock -- Founder and CEO

  Gilles Attia -- Legal Advisor

  Alan R Buckpitt -- Vice President of Pharmacology

  Irene Cortespuch

  Bora Inceoglu -- Vice President of Research

  Cindy McReynolds -- Project Manager

  William Schmidt -- Clinical Development

  Karen Wagner -- Principal Scientist

Company News

Jan 08 2016
EicOsis, LLC Receives $4 Million to Develop Novel Treatment for Diabetic Neuropathic Pain
Jul 10 2014
The pain of PIP2